<VariationArchive VariationID="982450" VariationName="NM_000020.3(ACVRL1):c.139dup (p.Arg47fs)" VariationType="Duplication" Accession="VCV000982450" Version="3" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-05-01" DateCreated="2020-10-30" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="970614" VariationID="982450">
      <GeneList>
        <Gene Symbol="ACVRL1" FullName="activin A receptor like type 1" GeneID="94" HGNC_ID="HGNC:175" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>12q13.13</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="51906944" stop="51923361" display_start="51906944" display_stop="51923361" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="52301201" stop="52317144" display_start="52301201" display_stop="52317144" Strand="+" />
          </Location>
          <OMIM>601284</OMIM>
          <Haploinsufficiency last_evaluated="2016-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=ACVRL1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2016-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=ACVRL1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000020.3(ACVRL1):c.139dup (p.Arg47fs)</Name>
      <CanonicalSPDI>NC_000012.12:51913174:CC:CCC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>12q13.13</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="51913174" stop="51913175" display_start="51913174" display_stop="51913175" variantLength="1" positionVCF="51913174" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="52306958" stop="52306959" display_start="52306958" display_stop="52306959" variantLength="1" positionVCF="52306958" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
      </Location>
      <ProteinChange>R47fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.11" sequenceAccession="NC_000012" sequenceVersion="11" change="g.52306960dup" Assembly="GRCh37">
            <Expression>NC_000012.11:g.52306960dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.12" sequenceAccession="NC_000012" sequenceVersion="12" change="g.51913176dup" Assembly="GRCh38">
            <Expression>NC_000012.12:g.51913176dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009549.1" sequenceAccession="NG_009549" sequenceVersion="1" change="g.10759dup">
            <Expression>NG_009549.1:g.10759dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000020.3" sequenceAccession="NM_000020" sequenceVersion="3" change="c.139dup" MANESelect="true">
            <Expression>NM_000020.3:c.139dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000011.2" sequenceAccession="NP_000011" sequenceVersion="2" change="p.Arg47fs">
            <Expression>NP_000011.2:p.Arg47fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001077401.2" sequenceAccession="NM_001077401" sequenceVersion="2" change="c.139dup">
            <Expression>NM_001077401.2:c.139dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001070869.1" sequenceAccession="NP_001070869" sequenceVersion="1" change="p.Arg47fs">
            <Expression>NP_001070869.1:p.Arg47fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_543" sequenceAccession="LRG_543">
            <Expression>LRG_543:g.10759dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_543t1" sequenceAccession="LRG_543t1">
            <Expression>LRG_543t1:c.138_139insC</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1940731944" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000020.3(ACVRL1):c.139dup (p.Arg47fs) AND Telangiectasia, hereditary hemorrhagic, type 2" Accession="RCV001262029" Version="1">
        <ClassifiedConditionList TraitSetID="2259">
          <ClassifiedCondition DB="MedGen" ID="C1838163">Telangiectasia, hereditary hemorrhagic, type 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-01-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000020.3(ACVRL1):c.139dup (p.Arg47fs) AND Cardiovascular phenotype" Accession="RCV002393672" Version="2">
        <ClassifiedConditionList TraitSetID="32616">
          <ClassifiedCondition DB="MedGen" ID="CN230736">Cardiovascular phenotype</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2014-07-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2018-01-01" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2020-10-30" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16752392</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32573726</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="2259" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3671" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Osler Weber Rendu syndrome type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Telangiectasia, hereditary hemorrhagic, type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Telangiectasia, hereditary hemorrhagic, type 2</ElementValue>
                <XRef ID="MONDO:0010880" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">HHT2</ElementValue>
                <XRef Type="MIM" ID="600376" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ORW2</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000511258" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000500010" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000241591" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509788" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000515716" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512240" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528531" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000515719" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528884" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9901" />
                <XRef ID="9901" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of multiple arteriovenous malformations (AVMs) that lack intervening capillaries and result in direct connections between arteries and veins. The most common clinical manifestation is spontaneous and recurrent nosebleeds (epistaxis) beginning on average at age 12 years. Telangiectases (small AVMs) are characteristically found on the lips, tongue, buccal and gastrointestinal (GI) mucosa, face, and fingers. The appearance of telangiectases is generally later than epistaxis but may be during childhood. Large AVMs occur most often in the lungs, liver, or brain; complications from bleeding or shunting may be sudden and catastrophic. A minority of individuals with HHT have GI bleeding, which is rarely seen before age 50 years.</Attribute>
                <XRef ID="NBK1351" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301525</ID>
                <ID Source="BookShelf">NBK1351</ID>
              </Citation>
              <Citation Type="general" Abbrev="HHT Foundation Int'l, 2011">
                <ID Source="PubMed">19553198</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Shovlin et al., 2000">
                <ID Source="PubMed">10751092</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="HHT Foundation Int'l, 2020">
                <ID Source="PubMed">32894695</ID>
              </Citation>
              <XRef ID="774" DB="Orphanet" />
              <XRef ID="C1838163" DB="MedGen" />
              <XRef ID="MONDO:0010880" DB="MONDO" />
              <XRef Type="MIM" ID="600376" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="32616" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="33389" Type="Finding">
              <Name>
                <ElementValue Type="Preferred">Cardiovascular phenotype</ElementValue>
              </Name>
              <XRef ID="CN230736" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2842562" SubmissionDate="2020-05-21" DateLastUpdated="2020-10-30" DateCreated="2020-10-30">
        <ClinVarSubmissionID localKey="ENST00000388922 c.138_139insC|OMIM:600376" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001439402" DateUpdated="2020-10-30" DateCreated="2020-10-30" Type="SCV" Version="1" SubmitterName="NIHR Bioresource Rare Diseases, University of Cambridge" OrgID="505998" OrganizationCategory="consortium" OrgAbbreviation="NIHR BR RD" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-01-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">32573726</ID>
          </Citation>
          <Comment>PVS1+PM2+PP4</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <TypePlatform>Next-gen sequencing</TypePlatform>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ACVRL1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000020.2:c.138_139insC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="600376" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>ThromboGenomics_HHT</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5183269" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2022-11-29">
        <ClinVarSubmissionID localKey="a303|MedGen:CN230736" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002702341" DateUpdated="2024-05-01" DateCreated="2022-11-29" Type="SCV" Version="2" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-07-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16752392</ID>
          </Citation>
          <Comment>The c.139dupC pathogenic mutation, located in coding exon 2 of the ACVRL1 gene, results from a duplication of C at nucleotide position 139, causing a translational frameshift with a predicted alternate stop codon (p.R47Pfs*122). This pathogenic mutation was first reported in an individual with severe epistaxis, telangiectasias, and a family history consistent with HHT (Bossler AD et al. Hum Mutat. 2006;27(7):667-75). In addition to the clinical data presented in the literature, since frameshifts are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ACVRL1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000020.2:c.139dupC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Finding">
          <Trait Type="Finding">
            <XRef DB="MedGen" ID="CN230736" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2842562" TraitType="Disease" MappingType="XRef" MappingValue="600376" MappingRef="OMIM">
        <MedGen CUI="C1838163" Name="Telangiectasia, hereditary hemorrhagic, type 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5183269" TraitType="Finding" MappingType="XRef" MappingValue="CN230736" MappingRef="MedGen">
        <MedGen CUI="CN230736" Name="Cardiovascular phenotype" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

